Irinotecán Sun (Irinotecan Hydrochloride Trihydrate)

Irinotecan, the active ingredient in Irinotecán Sun, is a topoisomerase I inhibitor presented as an injectable lyophilized powder for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, often as part of combination chemotherapy.

GNH USA supplies Irinotecán Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this essential anticancer agent. The company adheres to stringent quality standards and offers comprehensive logistics support for global distribution.

Irinotecan is used in oncology to target colorectal cancer pathways.

Metastatic colorectal cancer: used as part of combination chemotherapy to shrink tumors and extend patient survival. Advanced colorectal adenocarcinoma: administered with fluorouracil and leucovorin to improve response rates. Second‑line colorectal cancer therapy: employed when disease progresses after first‑line treatment to provide additional disease control.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: frequent feeling of sickness often occurring during or after infusion. - Vomiting: may accompany nausea and require anti‑emetic therapy. - Diarrhea: can be severe and may need supportive care. - Neutropenia: reduction in white blood cells increasing infection risk. - Alopecia: hair loss occurring during treatment cycles. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent medical attention. - Severe colitis: intense inflammation of the colon that can be life‑threatening. - Allergic reactions: including rash, itching, or anaphylaxis in rare cases. - Pulmonary toxicity: rare lung inflammation presenting with cough or shortness of breath. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.

When using Irinotecan, clinicians should observe several safety measures to minimize risks.

Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia. Liver function assessment: evaluate hepatic enzymes prior to treatment and periodically during therapy. Bowel obstruction risk: assess for pre‑existing gastrointestinal issues before administration. Antiemetic prophylaxis: give appropriate anti‑nausea medication to reduce nausea and vomiting. Avoid strong CYP3A4 inhibitors: do not co‑administer drugs that markedly increase Irinotecan exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure and toxicity. - UGT1A1 inhibitors (e.g., atazanavir): can raise active metabolite levels, heightening risk of neutropenia. - Concurrent myelosuppressive agents: additive bone‑marrow suppression may occur.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism, requiring dose adjustments. - Anticoagulants (e.g., warfarin): increased bleeding risk due to hepatic enzyme interactions. - Other chemotherapy agents: overlapping toxicities may need careful monitoring.